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Abstract
Osteoporosis is a chronic disease of the osseous system characterised by decreased strength of bone tissue, which in turn leads to increased
fracture risk. It has been demonstrated that osteoporosis affects more than 30% of women after the menopause (WHO, 1994). However,
the disease is also observed in men.
The primary goals of osteoporosis therapy include prevention of low-energy fractures and general improvement of quality of life. Any
patient with diagnosed osteoporosis requires, besides prevention, the application of proper treatment.
Of the available therapeutic options, the best are bisphosphonates, medical agents with well identified properties, therapeutic efficacy,
and safety which has been confirmed in many clinical studies. Therefore, they are recommended as first line drugs for osteoporosis. The
efficacy of oral preparations may be limited, due to low bioavailability, complications and adverse effects from the gastrointestinal tract. So
the parenteral administration of bisphosphonates is a valuable alternative. A fine example of such therapy is the intravenous administra-
tion of ibandronate. Short injection time periods and the relatively long, three-month intervals between administrations are unquestion-
able advantages of this therapy mode. In addition, the therapy does not  constrain a patient’s everyday activity, and simultaneously
provides regular contact with doctors and the therapeutic centre. Additionally, a good tolerance of the drug and its high therapeutic
efficacy, proven by appreciably reduced fracture risks, significantly improves the quality of life of patients suffering from osteoporosis.
This paper is a thorough review of current knowledge on the efficacy and safety of i.v. ibandronate in osteoporosis therapy, as presented
in the latest literature reports. (Pol J Endocrinol 2011; 62 (1): 51–60)
Key words: ibandronate, intravenous, osteoporosis
Streszczenie
Osteoporoza jest przewlekłą chorobą układu kostnego charakteryzującą się obniżeniem wytrzymałości kości, co z kolei prowadzi do
zwiększonego ryzyka złamań. Wykazano, że na osteoporozę choruje obecnie powyżej 30% kobiet po menopauzie (Światowa Organizacja
Zdrowia, 1994), ale dotyczy ona również mężczyzn.
Celem leczenia osteoporozy jest zapobieganie powstawaniu niskoenergetycznych złamań kości oraz poprawa jakości życia pacjentów.
Osoba, u której rozpoznano osteoporozę oprócz prewencji, wymaga również wdrożenia właściwego leczenia.
Spośród dostępnych opcji terapeutycznych kluczową rolę odgrywają bisfosfoniany, leki o najlepiej poznanych właściwościach, których
skuteczność terapeutyczna i bezpieczeństwo stosowania potwierdzono w licznych badaniach klinicznych i z tego względu zalecane są
jako leki pierwszego rzutu. Skuteczność doustnych preparatów może być ograniczona z uwagi na niską biodostępność oraz powikłania
i działania niepożądane ze strony przewodu pokarmowego. Alternatywę stanowi podawanie bisfosfonianów parenteralnie. Forma dożyl-
na ibandronianu stanowi doskonały przykład takiego leczenia. Zaletą podawania dożylnego jest krótki czas iniekcji i dość długa,
3-miesięczna, przerwa pomiędzy podaniami co jednocześnie nie utrudnia chorym codziennej aktywności oraz zapewnia relatywnie czę-
sty kontakt z ośrodkiem leczenia oraz z lekarzem. Dodatkowo dobra tolerancja leku i skuteczność w postaci zmniejszonego ryzyka zła-
mań w znaczny sposób może wpłynąć na jakość życia chorych. Obecny artykuł stanowi aktualny przegląd piśmiennictwa dotyczącego
skuteczności i bezpieczeństwa stosowania formy dożylnej ibandronianu w terapii osteoporozy.  (Endokrynol Pol 2011; 62 (1): 51–60)
Słowa kluczowe: ibandronian, postać dożylna, osteoporoza
Introduction
Osteoporosis is a chronic disease of the osseous system
of subclinical course. It has been demonstrated that os-
teoporosis affects more than 30% of women after the
menopause (WHO, 1994) but the disease is also ob-
served in men. According to the World Health Organi-
sation’s definition, osteoporosis corresponds to low
bone mineral density (BMD), responding in densitomet-
ric examination with a T-score L –2.5 SD vs. the peak
bone mass. At present, low BMD is one of the criteria to
start therapy, while fracture risk evaluation is also rec-
ommended. Discussions are also being held on the use
of calculators for ten-year fracture risk evaluation, tak-
ing into account other significant factors beside bone
mineral density [1–5].
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The goals of osteoporosis treatment include preven-
tion of low-energy bone fractures and improvement of
quality of life. As in any chronic disease, prevention is
necessary, with a particular consideration of healthy lif-
estyle, i.e. balanced diet with proper calcium supple-
mentation, physical activity and the elimination, total
or partial of stimulants. A patient in whom osteoporo-
sis has been diagnosed requires an effective therapy to
be implemented. Drug selection should take into con-
sideration not only medical contraindications but also
individual patient preferences, because osteoporosis
therapy is a long-term procedure, often lasting until the
end of the patient’s life. Bisphosphonates play the key
role among the available therapeutic options, as the
drugs with the best known properties. With their ther-
apeutic efficacy and safety, which have been confirmed
in numerous clinical studies, they are recommended as
first-line drugs for osteoporosis treatment [6–13].
The mechanism of action
Bisphosphonates demonstrate strong antiresorptive ef-
fects by inhibiting the activity and inducing apoptosis
of osteoclasts and, indirectly, by modulating the activi-
ty of osteoblasts [14]. They are used to treat many dis-
eases, including primary osteoporosis and many forms
of secondary osteoporosis, hypercalcaemia, which is
often a condition concomitant to neoplastic diseases,
neoplastic metastases to bones, Paget’s disease and bone
marrow diseases such as multiple myeloma. Due to the
presence of the phosphate group, bisphosphonates bind
with hydroxyapatite calcium.
Actually, two distinct molecular mechanisms explain
the mode of bisphosphonate activity on osteoclasts. The
effect, exerted by the activity of these drugs, depends
on the structure and localisation of the lateral chain
(Table I) [15]. Bisphosphonates, which do not contain the
amine group (tiludronate, etidronate, clodronate) are
metabolised by osteoclasts and macrophages to
a toxic form of the methylene-containing ATP (adenos-
ine-5’-triphosphate) analogue [16, 17]. Nitrogen-contain-
ing bisphosponates (aminobisphosphonates: ibandronate,
alendronate, pamidronate, risedronate, zoledronate) block
the pathway of mevalonate transformations, limiting in
this way prenylation of small GTP-ase proteins, which play
an important role in the activity of osteoclasts.
Because of these transformations, the activity of the
above-mentioned cells becomes limited, replaced by
their enhanced apoptosis. Moreover, ibandronate,
which belongs to this particular group, additionally in-
hibits the process of squalene synthesis. In a culture of
mouse osteoblasts and osteocytes, the above-mentioned
bisphosphonate suppressed apoptosis induction in
those cells [18].
Ibandronate in oral dosing
Ibandronic acid belongs to bisphosphonates of the third,
i.e. the latest generation. It demonstrates a much stron-
ger antiresorptive activity than that of alendronate, an-
other bisphosphonate, and one of which the use is fair-
ly widespread. The efficacy and safety of ibandronate
has been confirmed in two large clinical trials: BONE
and MOBILE [19, 20]. In the BONE trial (oral iBandr-
onate Osteoporosis vertebral fracture trial in North
America and Europe), 2,946 women with osteoporosis
were subjected to a three-year observation. All the pa-
tients had experienced menopause at least five years
previously, their BMD varied from –5.0 to –2.0 SD in
the lumbar spine, and each of them presented with at
least one vertebral fracture in Th4–L4 section. They re-
ceived an oral placebo or ibandronate in one of the avail-
able forms of administration: 2.5 mg/d or 20 mg every
second day (in total: 12 doses for three months). After
three years, the incidence of new vertebral fractures sig-
nificantly decreased in the therapeutic groups, amount-
ing to 4.7% in the group with daily dosage and 4.9% in
the group with drug administration every 48 hours, vs.
9.6% in the placebo group. A reduction of the relative
risk (RR) for new vertebral fractures was demonstrated
by 62% and 50% for daily dosing and for dosing every
second day, respectively. Moreover, significantly low-
er RR of symptomatic vertebral fractures was also ob-
tained for both groups (49% and 48% for ibandronate
once daily and once every 48 hours, respectively). The
results of a post hoc analysis proved that daily use of
the drug reduced the risk of non-vertebral fractures
by 69% in a group of patients with increased risks
(BMD of the femoral neck — T-score £ –3.0). Ibandr-
onate was well tolerated during the whole period of
the trial [19].
The MOBILE (Monthly Oral iBandronate In Ladies)
trial was a randomised, two-year study, double-blind-
ed and comparing the efficacy of oral ibandronate with
various dosing modes (2.5 mg/d, 50 mg/month, 100 mg/
/month or 150 mg/month). The trial was performed in
a group of 1,609 women with post-menopausal os-
teoporosis. After two years of therapy, similar effects
were observed in the therapy with ibandronate 2.5 mg
once daily and 50 mg, 100 mg, once a month, while sig-
nificantly better effects regarding increased BMD in the
lumbar spine were noted with the dose of 150 mg (in-
crease by 5.0%, 5.3%, 5.6% and 6.6%, respectively).
A statistically significant increase of BMD within the
total hip, the femoral neck and the trochanter of the
femoral bone was noted in all the groups, with the most
beneficial effect coming with the dose of 150 mg/month
[20]. Considering the scarcity of data on the efficacy of
ibandronate in the prophylactics and therapy of os-
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teoporosis in men, attention should be paid to recently
published data from the randomised STRONG (the
STudy Researching Osteoporosis iN Guys) study. That
observation comprised 132 men with primarily low
BMD and diagnosed hypogonadism. The patients re-
ceived oral ibandronate, 150 mg/month or a placebo for
12 months. A statistically significant increase of BMD
was noted in the lumbar spine (3.5 vs. 0.9%; p < 0.001)
and in the hip (1.8 vs. –0.3%; p < 0.001) in the thera-
peutic group [21].
Studies of patient preferences provided the follow-
ing results: BALTO I and II (Bonviva Alendronate Trial
Table I. Biochemical structure and division of bisphosphonates according to antiresorptive potential
Tabela I. Struktura biochemiczna i podział bisfosfonianów według potencjału antyresorpcyjnego
Generation Chemical structure Biochemical Drug Antiresorptive
— lateral chain structure potential
I Alkyl Etidronate 1
Halide Clodronate     10
II Cyclic Tiludronate 10
Cyclic Pamidronate 100
Amine Alendronate 100–1000
III Pyridinyl Cyclic  Risedronate 1000–10 000
Cyclic Ibandronate 1000–10 000
Cyclic Zoledronate ≠10 000
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in Osteoporosis) [22], PERSIST (Persistence Study of
Ibandronate versus Alendronate) [23], CURRENT [24]
and PRIOR [25] revealed that patients preferred iban-
dronate therapy at 150 mg doses, received once
a month rather than more frequently received alendr-
onate. That effect can partially be explained by a better
tolerance for the less frequently received drug. More-
over, the annual observation in the MOTION trial dem-
onstrated a comparable therapeutic efficacy of month-
ly ibandronate and weekly alendronate. BMD increase
obtained after 12 months of therapy for ibandronate and
alendronate was 5.1% and 5.8%, respectively, in the
lumbar spine section and 2.9% and 3.0%, respectively
in the hip. Both therapies were well tolerated by the
patients [26, 27].
Ibandronate in intravenous application
Preclinical studies
Due to the potential risk of acute renal failure (ARF),
most bisphosphonates are administered in slow-rate
intravenous infusions. It has been observed in some
studies that, following fast intravenous injection or us-
ing big doses, some older bisphosphopnates may in-
duce ARF [28–30]. However, unlike other bisphospho-
nates, ibandronate can be administered in a quick bo-
lus, without any negative effects on renal functions.
Pfister et al. [31] studied the nephrotoxic properties
of intravenously administered ibandronate and zoledr-
onate in rats, using minimal nephrotoxic doses of ei-
ther compound. The rodents were administered iban-
dronate (1 mg/kg) or zoledronate (1 and 3 mg/kg), ei-
ther intermittently, at three-week intervals, or in a sin-
gle dose for 25 weeks. In the case of ibandronate, the
nephrotoxic effects were minimal and independent of
the applied administration scheme. On the contrary,
renal lesions in the zoledronate-treated rats were dis-
tinctive and more intense in the subgroup with the in-
termittent administration scheme [31]. Ibandronate safe-
ty with regards to nephrotoxicity was also evaluated in
patients with bone metastases and neoplastic hypercal-
caemia in the course of breast carcinoma. Using two-
hour infusions of ibandronate in 6 mg doses, a low per-
centage of acute renal complications was observed [32].
Those data were comparable with placebo results [33–
–35] and the applied doses were much higher from the
therapeutic doses, currently used in osteoporosis ther-
apy. In another clinical project, daily infusions of iban-
dronate: 4 mg doses in a two-hour infusion, repeated
for four subsequent days or 6 mg doses in one-hour in-
fusion, repeated for three subsequent days, to alleviate
bone pains in patients with bone metastases, were not
associated with any renal lesions [36]. Studies in healthy
volunteers and in patients with neoplastic metastases
to bones, in the course of breast carcinoma or multiple
myeloma, have also confirmed the safety of single,
15-minute infusions of ibandronate in 6 mg doses [37,
38]. In another study, no renal complications were ob-
served after quick injections of ibandronate in 2mg or
3 mg doses in patients with metastases to the bone sys-
tem [32, 33].
Clinical studies of intravenous ibandronate
Thiébaud et al. [39] were the first to study the effica-
cy of intravenous ibandronate in the therapy of meno-
pausal osteoporosis. In a planned, randomised, double-
blinded trial, 125 women participated (mean age
64 years). The patients received the tested drug in dos-
es of 0.25 mg, 0.5 mg, 1 mg and 2 mg or a placebo every
three months. Additionally, each of the participating
patients received a calcium supplement. After
12 months, in the groups of patients on ibandronate,
an increase of BMD in the lumbar spine was noted by
2.4%, 3.5%, 3.7% and 5.2%, respectively for the increas-
ing doses of the compound. The obtained results were
significantly higher vs. those in the control group:
0.5 mg (p < 0.05), 1 mg (p < 0.005), 2 mg (p < 0.001).
The study did not show any statistically significant dif-
ferences among the therapeutic (i.e. drug-receiving)
groups. Unlike with the spine, BMD changes in the fem-
oral neck were, in the course of treatment, comparable
in all the groups. However, the favourable effects of the
increasing doses on the proximal epiphysis of the fem-
oral bone were also successfully demonstrated for its
remaining parts. An increase of BMD by 1.8% and 2.9%
in the total hip and by 2.7% and 4.2% in the trochanter,
was obtained for 1 and 2 mg doses respectively, of the
tested drug. The dynamics of bone marker concentra-
tions, observed in the course of therapy, seem to con-
firm the favourable effects of ibandronate. After the first
month of treatment, the concentrations of C-terminal
telopeptide of collagen type I (CTX) and of the N-ter-
minal telopeptide of collagen I (NTX) in urine were re-
duced by 33% (0.25 mg), 44% (0.5 mg), 57% (1 mg) and
66% (2 mg), showing, however, gradual increases as the
time of subsequent injection approached. Moreover, the
highest (2 mg) dose caused a significant and permanent
reduction of the above-mentioned bone markers by 40%
(p < 0,005). Despite fairly promising results, the study
was too short and the groups included only 25 patients
each, which is insufficient for proper statistical signifi-
cance [39].
Taking into account the promising results of a 12-month
observation, another project was implemented to pro-
vide evidence for the antifracture effects of intravenous-
ly administered ibandronate [40]. The study of antifrac-
ture efficacy of intravenous ibandronate was a three-
year, randomised, double-blind study of 2,862 women
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aged 55–76 with post-menopausal osteoporosis, who
met the following criteria: 1–4 vertebral fractures in his-
tory and a T-score from –2.0 to –5.0 SD in, at least, one of
their lumbar vertebrae. The participants, beyond
a calcium supplement (500 mg/day) and vitamin D3
(400 IU/d) received either a placebo or ibandronate in
doses of 0.5 mg or 1 mg every three months. Using both
doses of the drug for three years, a statistically insignif-
icant increase of BMD was noted in the lumbar spine
by 2.9% and 4.0%, respectively vs. placebo. A similar
effect was noted in the hip (Total Hip), i.e. 2.3% and 3.6%.
Nor did bone resorption marker concentrations present
a positive picture, demonstrating concentration drops
by 41.4% and 45%, respectively, measured before sub-
sequent injections. Therefore, the confirmed slight an-
tifracture effect should not be surprising. The incidence
of new fractures after three years of therapy was 10.7%,
8.7% and 9.2% for the groups receiving a placebo,
0.5 mg and 1 mg of the drug. The differences were sta-
tistically insignificant. While performing a per-proto-
col analysis, it was possible to obtain a 26% (p = 0.0549)
fracture risk decrease for 1 mg dose of the drug. Similar
data was obtained for non-vertebral fractures and hip
fractures, but the statistical power of the study did not
allow for a reliable analysis of those end-points [40]. The
results of the previously discussed study led to a con-
clusion that a favourable antifracture effect required
a higher dose of the agent. A group of 520 women with
osteoporosis after menopause, their ages varying be-
tween 55 and 75 years, took part in the two-year Inter-
mittent Regimen intravenous Ibandronate Study (IRIS).
The patients received either a placebo or ibandronate
in intravenous doses of 1 or 2 mg. After the first year of
the study, a statistically significant BMD increase was
observed, both in the lumbar spine ([5.0% and 2.8% vs.
–0.04%] and in the proximal epiphysis of the femoral
bone [2.9% and 2.2% vs. 0.6%]) for both applied doses,
i.e. 2 mg and 1 mg of ibandronate) respectively vs. pla-
cebo. Bone marker concentration changes: CTX and
osteocalcin, remained conformable with BMD chang-
es. The therapy was well tolerated. Similarly small num-
bers of adverse effects were noted in the ibandronate
group and in the placebo group and, most importantly,
no renal toxicity was induced by the drug in the ap-
plied doses. The study duration was planned for two
years but, due to the unfavourable results of the three-
year observation of antifracture efficacy and to the ear-
lier proven assumptions, the study programme was fin-
ished after one year of observation [41].
In the meantime, several other studies were under-
taken into the efficacy and safety of intravenous iban-
dronate. Stakkestad et al. [42] evaluated the efficacy of
the therapy in a group of 629 women at a mean age of
54.75 and a maximum 10 years after menopause, in
whom osteoporosis had earlier been excluded. A ran-
domised study with placebo and double-blinded, was,
as in the IRIS Project, planned for two years. The ap-
plied therapy was to have prevented osteoporosis. The
women received the drug in 0.5 mg, 1 mg and 2 mg
doses every three months. After the first year of thera-
py, in both studied areas, i.e. the lumbar spine and the
hip, a significant BMD increase was found for all the
drug doses, with a clear dose-dependent effect. Neither
study was continued, due to the already published data
from the above-mentioned project of Recker et al. [40]
about the lack of therapeutic efficacy of ibandronate in
too small a dose: 0.5 mg and 1 mg.
Ringe’s team [43] evaluated, in a three-year open
study, the therapeutic effects of intravenous ibandr-
onate in patients with steroid-induced osteoporosis.
There were 115 participants, who received at least
7.5 mg of prednisone per day for the last two years. The
patients, receiving calcium supplementation (500 mg/
/day), were assigned to two groups, one of which was
administered alphacalcidiol in a dose of 1 mcg/d or iban-
dronate in a dose of 2 mg every three months. In pa-
tients treated with bisphosphonate, a statistically sig-
nificant BMD increase was demonstrated, amounting
to 13.3% in the spine and 5.2% in the femoral neck vs.
2.6% and 1.9% in the group on an alternative therapy.
Despite the fact that the primary end-point of the project
was not antifracture effect evaluation, an evidently low-
er prevalence of vertebral fractures was noted in the
ibandronate group vs. alphacalcidiol (8.6% vs. 22.8%).
Moreover, the study in question for the first time
proved the efficacy of intravenous bisphosphonates in
fracture prevention for patients with steroid-induced
osteoporosis. The patients who received ibandronate
less frequently reported back pains with a significantly
lower height reduction [43]. Other, smaller clinical stud-
ies are also worth mentioning, the primary end-points
of which were the concentrations of bone markers.
Christiansen et al. [44] applied ibandronate in 73 wom-
en after menopause and without diagnosed osteoporo-
sis. The patients received either a placebo or the drug
in a dose of 1 mg or 2 mg, twice, with a 84-day interval.
Serum CTX and osteocalcin concentrations were mea-
sured at 19 time points. Following the drug administra-
tion, CTX concentration decreased to obtain the lowest
level on the seventh day after administration, while,
after approximately two weeks from injection, its grad-
ual increase was observed. Immediately before a sub-
sequent drug administration, its concentration was
about 16% and 20% lower for a 1 mg and a 2 mg dose,
respectively vs. that before therapy. Osteocalcin values
in the therapy groups were characterised by a slow de-
crease, where the lowest concentration (–35%) was ob-
served five months after the study onset. The authors
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of the project highlight the relatively short period of re-
sorption suppression (CTX) vs. bone formation (osteo-
calcin), as the factor at the root of the failure of the three-
year antifracture project by Recker’s team [40], which may
raise certain doubts in the light of later data [44].
The Study of Different Regimens of Intravenous
Administration of Bonviva (Ibandronate) in Women
With Post-Menopausal Osteoporosis (DIVA) is by far
the most important project looking at the registration
of  intravenous ibandronate. That randomised, double-
blinded study was to demonstrate a similar efficacy
(non-inferiority) of intravenous ibandronate vs. daily
oral form.
A group of 1,395 women, aged 55–80, were quali-
fied to the study. All the patients had experienced meno-
pause at least five years previously and had osteoporo-
sis, diagnosed from a T-score parameter in the lumbar
spine, below –2.5 SD but not below –5.0 SD. The pa-
tients were divided into three groups, receiving oral
ibandronate in a dose of 2.5 mg/day and intravenous
ibandronate in doses of 2 mg or 3 mg every two or three
months, respectively. All the participants were provi-
ded with oral calcium (500 mg/d) and vitamin D3
(400 IU/d) supplementation. A two-year follow-up dem-
onstrated intravenous ibandronate to have been not
only non-inferior but to have an even higher efficacy in
the therapy of osteoporosis. Bone density in the lum-
bar spine increased by 6.4%, 6.3% and 4.8% in the
groups treated with intravenous 3 mg and 2 mg doses
and with 2.5 mg/d dose, respectively, where the intra-
venous therapeutic effect attained the level of signifi-
cance (p < 0.001). Analogous results were obtained,
comparing BMD values in the hip and in the femoral
bone trochanter (p < 0.001).
However, no significant BMD differences were
found in the femoral neck region. The efficacy of intra-
venous doses was similar and the observed differences
insignificant. A similar, statistically significant, fall of
CTX, from 53.4% to 59.9%, was observed in all the ther-
apeutic groups [45]. In an observation of a subgroup of
109 women, bone biopsy was performed for histomor-
phometric analysis. Following the results from 89 stud-
ied samples and of their comparison with control ma-
terial, no damage in bone microarchitecture nor im-
paired bone mineralisation/formation was observed.
The collected material demonstrated only features of
certain remodelling suppression in results of the thera-
py [46]. The DIVA study was initially not designed to
evaluate differences of antifracture efficacy in both ther-
apy forms. Despite the difference not being statistically
significant, observed in the incidence rates of all frac-
tures after two years of the study, a post hoc analysis of
the study, performed by Sambrook’s et al. [47], demon-
strated a significant, 43% reduction of nonvertebral
fracture risk (p < 0.05) in the group on intravenous bis-
phosphonate vs. the patients on oral therapy [47].
A metaanalysis of the results, obtained in phase III clini-
cal studies of ibandronate efficacy and safety (BONE,
MOBILE, the study of antifracture efficacy of intrave-
nous ibandronate [40], DIVA), presented with antifrac-
ture efficacy of both the oral form, in a dose of 150 mg/
/month, and the intravenous form (2 mg every two
months and 3 mg every three months). The participants
in the studies, using the above-mentioned forms of the
drug, demonstrated an almost 30% reduction of the
non-vertebral fracture risk and of all symptomatic frac-
ture risks after two years [48]. Because most studies into
the efficacy of ibandronate, especially of its intravenous
form, have been performed on female populations, the
project by Lama et al. deserves special attention [49].
Fourteen men were submitted to a two-year open treat-
ment with intravenous ibandronate in 2 mg doses, ad-
ministered every three months. After the observation,
an increase of BMD was demonstrated in all the studied
areas: in the lumbar spine by 6.7% (p < 0.001), in the
trochanter by 3.2% (NS) and in the femoral neck by 1.4%
(NS). The concentrations of bone turnover markers, i.e.
CTX and osteocalcin, were reduced by 30–45% and 30%,
respectively. The obtained data, however promising, are
unsatisfactory in terms of evaluating the efficacy of anti-
osteoporotic therapy with intravenous ibandronate in
men. It is necessary to design for that purpose a ran-
domised, double-blind study [49]. Attempts have also
been undertaken to apply intravenous ibandronate in
patients after transplantations. Kaemmerer et al. [50]
administered ibandronate in a 2 mg dose every three
months for 12 months to 34 patients after liver trans-
plantation. In the therapeutic group, a significantly low-
er incidence of new fractures and no BMD decreases
were demonstrated vs. the control [50].
Another team [51] obtained a favourable effect on
BMD loss prevention and decreased fracture incidence,
administering the above-mentioned bisphosphonate in
the same dose to patients after heart transplantation.
After 12 months of the therapy, the incidence of new
vertebral fractures in the therapeutic group was 13%
vs. 53% in the control group, a difference that was sta-
tistically significant [51].
Safety and tolerance
Ibandronate, administered intravenously in three-
month intervals, is, in general, well tolerated by patients.
In a three-year study of the antifracture efficacy of the
medical agent [40], patients reported adverse events
(AE), mostly mild and moderate ones, with a compara-
ble incidence rate in all the studied groups. A slightly
higher reportability, i.e. 3 1% in the therapeutic groups,
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was accounted to: muscular pains, sinusitis, asthenia,
limb pains and adverse reactions to injections. A total
of 253 out of 2,862 participants discontinued their treat-
ment because of AE: in the group using 1 mg of the
drug  105 participants, , in the group receiving 0.5 mg
of ibandronate 77 participants and in the group receiv-
ing a placebo 71 participants. The incidence of therapy-
related adverse effects was higher in the patients on
therapy, amounting to 17% and 15% for 1 mg and
0.5 mg of ibandronate, respectively vs. the patients in
the placebo group,  10%. In the great  majority, adverse
effects included muscular pains and reactions to injec-
tions. In as many as 25% of the participants, serious
adverse events (SAE) occurred, but their incidence rate
was similar in all the studied groups: 23.2% (1 mg),
25.2% (0.5 mg) and 26.7% (placebo). Among the above-
mentioned severe adverse events, only five patients
(three in the placebo group) experienced SAE, poten-
tially drug-related: stroke (the 1 mg group), cataract (the
0.5 mg group), gastro-intestinal disorders, skin lesions
and hypertension (the placebo group). Twenty-nine
(1%) patients died during the study but none of the
deaths was related to the therapy [40].
In the IRIS study [41], in which slightly higher iban-
dronate doses were used, a fairly high, but similar in all
the groups, incidence of adverse events was observed.
In total, 70%, 75% and 71% of AE were recorded for pa-
tients, using the drug in 2 mg and 1 mg intravenous dos-
es and receiving the placebo, respectively. The most fre-
quently reported ailments included: back pains and ar-
thralgias, infections of the upper respiratory tract,
pseudoinfluenzal symptoms and headaches. An elevat-
ed incidence of arthralgias and fever was found in pa-
tients on active treatment. In turn, drug-related AEs were
observed in 19% (the 2 mg intravenous group), 20% (the
1 mg intravenous group) and 14% (the placebo group).
The differences in the incidence of treatment-relat-
ed adverse events among the groups were statistically
insignificant, although some positive trend was main-
tained, taking into account the incidence of limb pains,
myalgias and arthralgias in patients on intravenous ther-
apy vs. placebo. The above-mentioned symptoms were
predominantly short in duration, being most probably
associated with the acute phase reaction, which had
been observed earlier, when larger intravenous doses
of aminobisphosphonates were used.
It is even more important that the majority of such
reactions occurred in the study participants only once,
following the first drug administration, where the in-
tensity of ailments was mild or moderate, regressing
within a maximum of seven days from injection. No
drug-related SAE was noted in the study by Adami et
al. [41]. Analysing the results of biochemical measure-
ments, no toxicity features were identified with regards
to the administered drug, including renal dysfunction.
In turn, a refusal to continue the therapy as the result
of adverse episodes was more frequently observed in
the therapeutic patients: 6%, 3% and 2% of the partici-
pants gave up further treatment in the groups using
the drug in the doses of 2 mg and 1 mg and placebo,
respectively.
During the two-year DIVA study [45], a comparable
incidence of treatment-related adverse episodes was
observed, as well as of such episodes which caused ther-
apy withdrawal in all the studied groups. The most fre-
quent treatment-related side effects, as found in previ-
ous studies, were back pains and arthralgias. Nasophar-
yngitis was an adverse effect relatively frequently re-
ported by the patients.
No episode of osteonecrosis of the jaw was noted in
any of the groups over the course of a two-year obser-
vation. This particular adverse event may become a sig-
nificant problem in the treatment with intravenous bis-
phosphonates, although it much more frequently con-
cerns patients with metastases into bones or neoplastic
hypercalcaemia in the course of breast cancer or multi-
ple myeloma [52, 53]. In the retrospective analysis by
Abu-ID et al. [52], only seven cases of jaw osteonecrosis
were found in patients on chronic therapy with oral or
intravenous ibandronate [52]. An equally low rate of
necrosis after ibandronate was demonstrated in anoth-
er study [53]. Only two cases of this complication after
ibandronate were described unitil 2006, and one of these
two patients had also been using zoledronate in a chron-
ic therapy mode [53].
Taking into account the obtained data, we assume
that the risk of occurrence of this dangerous complica-
tion in patients treated with ibandronate to be very
small. Prior to application of the therapy, patients are
recommended to check their oral caviy and major den-
tal procedures are avoided, if not urgent. In the DIVA
study [45], the incidence of severe adverse events was
similar in all the studied groups, amounting to: 14.4%;
16.3% and 13.2% for a 3 mg dose every three months,
2 mg dose every two months and oral dose of 2.5 mg/
/day. A total of 11 SAEs was recorded, of which nine
resulted in patient death. A similar percentage of partic-
ipants in the groups gave up further treatment (17–21%),
also because of AEs (9.8–11.7%). Similarly as in the IRIS
study (with placebo control), pseudoinfluenzal symp-
toms occurred more frequently in the patients who were
using the drug intravenously. However, they were more
frequently reported in the group with the dose of 2 mg
every two months (15.6%) than 3 mg every three
months (10%) and with the oral dose of 2.5 mg/day
(4.3%). The intensity of the above-mentioned symptoms
was slight or medium and they usually disappeared
after seven days from injection. No case of acute renal
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failure was noted in the course of the study and the
incidence rates of renal parameters lowering were com-
parable (21–23% of the participants) [45]. Reports have
appeared in recent years about an increased risk of atri-
al fibrillation in patients on chronic bisphosphonate
therapy. The results of the very few studies dealing with
the complication have not been entirely clear [54, 55].
An analysis of data from four clinical studies (BONE,
The study of antifracture efficacy of intravenous iban-
dronate [41], MOBILE, and DIVA), found a similarly low
incidence, i.e. < 1%, of atrial fibrillation, both as adverse
events and serious adverse events in patients using iban-
dronate and a placebo [56].
Derman et al. [57] examined the effect of switching
from oral alendronate once a week to ibandronate ad-
ministered oraly once a month or inravenously every
3 months on the incidence of gastrointestinal adverse
events. In 70 % of patients who experienced gastrointes-
tinal disorders during alendronate therapy, a reduction
in the frequency and severity of those symptoms were
observed after introducing either intravenous or oral
ibandronate. After 10 months of treatment with iban-
dronate, 90% of patients reported a reduction in gas-
trointestinal symptoms.
Summary
Oral bisphosphonates have gained an established posi-
tion in the therapy of osteoporosis. Their efficacy and
safety of use have been supported by the results of nu-
merous clinical studies and by practical observations of
their many-year applications in patients all over the
world [1–8]. However, the period of their use is rather
limited due to low bioavailability, complications and
adverse symptoms from the gastro-intestinal tract [58–
–62]. The oral use of bisphosphonates requires strict
compliance with recommendations, including fasting
after tablet intake and keeping the body in an erect
position for longer time periods, which can be associat-
ed with some discomfort. All these inconveniences, the
patient’s general state and her/his individual preferences
may impede therapy acceptance by the patient, and this
usually compromises the patient’s compliance and clini-
cal efficacy in everyday realities of life [63, 64]. The elon-
gation of the time interval between doses to one week
(alendronate) met patient expectations only in part; fur-
ther progress towards optimisation of osteoporosis ther-
apy was the introduction of oral ibandronate protocol
with monthly dosing.
Patients with osteoporosis or osteopenia were quali-
fied to the PRIOR study, all of them having previously
discontinued their therapy with another oral bisphos-
phonate. The participants were offered a choice between
two forms of therapy: intravenous Bonviva, administered
every three months, or the oral form of the drug, received
once a month. They could also switch (once) from the
first selected drug to another one in the course of study.
As many as 82.9% of the participants who decided on
the intravenous form, remained with the primary op-
tion of therapy, while 69.7% of the patients remained
with the primariliy selected oral therapy [25].
The intravenous administration of the drug elimi-
nates the risk of gastro-intestinal adverse effects and
increases patient’s compliance, most probably for the
relatively rare drug applications with the relatively fre-
quent contacts with the drug applying centre. Addition-
ally, taking into account its outstanding bioavailability
and high antifracture efficacy, it can indeed be recom-
mended for patients with increased fracture risks. In-
travenous ibandronate is an excellent example of such
therapy [25]. The drug is administered every three
months, which compels a patient’s regular attendance
at the medical centre and enables frequent contacts with
the doctor, whose role is to motivate the patients to con-
tinue the therapy, unless adverse symptoms occur,
which would require therapy changes. The visit after
the first drug administration is very important for the
frequently observed pseudoinfluenzal symptoms. The
patient should be informed of the slight risk of their
recurrence during subsequent drug applications. Both
the oral and the intravenous form of ibandronate
present with proven antifracture effectiveness and, be-
cause of the less frequent administration, they do not
impose any necessity to change lifestyle on the treated
patient. Results of the previously discussed clinical stud-
ies BALTO I and II, CURRENT, PERSIST and PRIOR,
unequivocally indicate that patients more frequently
choose oral ibandronate, administered once a month,
rather than drugs of the same group administered ev-
ery day or once a week.
Both forms of ibandronate, i.e. oral and intravenous,
are good alternatives in the treatment of osteoporosis,
especially for those patients who either do not want or
cannot receive other bisphosphonates. The advantage
of intravenous administration is its outstanding bioavail-
ability, the short time of injection and the fairly long,
three-month interval between administrations.
This  does not impede a patient’s everyday activity,
but also ensures relatively frequent contact with the ther-
apeutic centre and the doctor. Additionally, the con-
firmed good tolerance of the drug and its effectiveness,
manifested by reduced fracture risks, may considerably
improve the quality of life of treated patients, something
which is a key element in the therapy of osteoporosis.
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